InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B
China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115...
NMPA Releases 56th Batch of GQCE Reference Drugs, Including 14 Injectables
The National Medical Products Administration (NMPA) has released the 56th batch of reference drugs for...
MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline
China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8...
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...
ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital
Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution,...
Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion
Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make...
Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital
Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...
Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech
Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...
Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...
Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment
Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and...
Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development
Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...
Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...
Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...
Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang
China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...
Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...
Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study
China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National...
Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors
The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...
Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...
Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE
The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...